Special Situation: Bouygues price reflects the chances of a sale of Bouygues Telecom - Short EN: FP / Long NUM: FP, ORA: FP and ILD: FP
On January 5, Bouygues confirmed earlier press comments that it was in early-stage talks with Orange for a potential combination of the two companies. We believe Orange-Bouygues deal can go through although there are still a lot of obstacles to meet including regulatory risks combined with uncertainties regarding the ability of Orange to make asset disposals on good terms to a third party player.
In this report we do not attempt to take a view on the likelihood of such deal but we rather argue that a merger between Bouygues and Orange is already priced in Bouygues share price. In other words, if consolidation occurs, we see little upside whereas the downside risk in a no-consolidation scenario would be considerable based on the current share price. We base our thesis on a SOTP analysis for Bouygues in which we take the Telecom Business at the maximum estimated deal price (€10bn, 13.5x EV/EBITDA 2015). This analysis shows that in a best case scenario the discount to NAV is 24%. The question is of course what discount would be adequate for Bouygues post the telco disposal. While there is no “correct “answer, we believe that given the portion of the unlisted assets in addition to the expected structure of the deal in which Bouygues will have a minority stake in orange, the appropriate discount should be at least 15-20% (in a strong market). Another variable is what use will Bouygues make of the cash from the sale. In any event, to our view, the current level doesn’t not leave room for meaningful upside.
Full report attached.
After Hours Summary: CPXX +346.4%, CTIC +30.8%, IMMU -15.1%, NVIV -10.9% following newsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: SZYM +31.6% (also announces multi-year global supply agreement with Unilever), BORN +23.5%, AMPH +14.9%, ESI +14.1%, INGN +12.7%, BDE +12.4%, ARTX +5.1%, PFSW +4.9%, VSLR +4.3%,
Companies trading higher in after hours in reaction to news: CPXX +346.4% Announced 'positive' results from Phase 3 trial of VYXEOS Liposome for Injection in patients with high-risk acute myeloid leukemia. CTIC +30.8% Provides update regarding the availability of pacritinib to certain patients with myelofibrosis, says FDA has expressed interest in allowing patients to continue receiving pacritinib under a single patient IND program. OUTR +10.5% To explore strategic and financial alternatives; increases quarterly dividend to $0.60/share from $0.30/share. BCRX +5.4% D.E. Shaw & Co discloses 5.1% passive stake. AVP +2.5% To reduce headcount by 2,500 positions as part of 3-year plan.
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: MNKD -15.8%, DCO -7.6%, DOV -2.1%, JMBA -2%, KANG -1%,
Companies trading lower in after hours in reaction to news: IMMU -15.1% To terminate the Phase 3 PANCRIT-1 trial with yttrium-90-labeled clivatuzumab tetraxetan in patients with metastatic pancreatic cancer. NVIV -10.9% Commences an underwritten public offering of common stock for unspecified amount. APPY -5.8% Terminates proposed transactions with Strand Life Sciences. TCON -5.4% Initiates phase 1B study of TRC105 in patients with lung cancer. CBPX -3.9% Announces 4.5 mln share secondary common stock offering by selling shareholders & 900,000 share repurchase. PRTY -2.7% Acquires Festival SA for ~$5 mln.